OC015-Up-TiTraTiON STUDy WiTh pONeSiMOD, a SeleCTiVe S1p1 reCepTOr MODUlaTOr, TO aSSeSS iTS MaxiMUM TOleraTeD DOSe iN healThy SUbjeCTS M. Hoch 1* ; D. D'Ambrosio 1 ; D. Wilbraham 2 ; P. Brossard 1 ; and J. Dingemanse 1 1 Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; and 2 Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom Introduction: Ponesimod is a selective sphingosine-1 phosphate (S 1 P 1 ) receptor modulator currently in clinical development for multiple sclerosis and plaque psoriasis. The aim of this study was to assess the maximum tolerated dose of increasing multiple doses (3-day titration steps) of ponesimod in healthy subjects. Patients (or Materials) and Methods: This was a single-center, double-blind, placebo-controlled, randomized, parallel-group, up-titration study in healthy male and female subjects (n = 16). The subjects received ascending oral doses either of ponesimod (n = 12) or placebo (n = 4) once daily for 3 days at each dose level (10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg). The pharmacodynamics of ponesimod were assessed by measuring the total lymphocyte count. The safety and tolerability was evaluated by monitoring adverse events, assessing standard blood chemistry and hematology laboratory variables, 12-lead ECG recordings and telemetry, measuring of vital signs, and pulmonary function tests (PFTs). Results: A plateau in mean lymphocyte count reduction from baseline of ~70% was reached at the 40-mg dose level. The most frequent adverse events, all of mild to moderate intensity, were chest discomfort (experienced by 58% of subjects), headache (50%), dizziness (42%), dyspnea (42%), abdominal pain (33%), and night sweats (25%). A transient decrease in heart rate was observed after administration of the first 10-mg ponesimod dose (-9 bearts/min at 1.5 hours postdose [placebo, -2 beats/min]). After up-titration from 10 to 20 mg (-7 beats/min at 1.5 hours postdose [placebo, -5 beats/min]) and following up-titration to higher doses, the decrease in heart rate with ponesimod was similar to placebo, suggesting that desensitization to the heart rate effect had occurred. A dose-dependent decrease in PFTs was observed and reached a plateau with 60-mg ponesimod (maximal mean decrease of 1.24 L [-30.5%] in forced expiratory volume in 1 second [FEV 1 ] and 0.70 L [-13 .7%] in forced vital capacity [FVC] ). At the dose levels of 80 to 100 mg, several subjects reported chest discomfort and dyspnea. The effects on heart rate, lymphocytes, and PFTs were fully reversible and reached baseline values within 10 days after discontinuation of treatment. Conclusion: Ponesimod was tolerated by subjects exposed to doses of 10 to 100 mg during the 18-day up-titration regimen. The maxi-e7 mum tolerated dose was approached at 80 to 100 mg due to symptoms of chest discomfort and dyspnea. These results reveal a good safety margin to the highest dose selected for Phase 3 (20 mg). Disclosure of Interest: M. Hoch: Shareholder of Actelion Pharmaceuticals Ltd, employee of: Actelion Pharmaceuticals Ltd. D. D'Ambrosio: Shareholder of Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals Ltd. D. Wilbraham: Employee of Quintiles Drug Research Unit at Guy's Hospital. P. Brossard: Shareholder of Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals Ltd. J. Dingemanse: Shareholder of Actelion Pharmaceuticals Ltd, employee of Actelion Pharmaceuticals Ltd.
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